Indivior Pharmaceuticals, Inc. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d698dcae-0731-4248-b86a-eb2fe73f0770/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.2B | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-012237 |
| FY 2024 | $1.2B | 2024-01-01 – 2024-12-31 | evidence 0001625297-25-000016 |
| FY 2023 | $1.1B | 2023-01-01 – 2023-12-31 | evidence 0001625297-25-000016 |
| FY 2022 | $901.0M | 2022-01-01 – 2022-12-31 | evidence 0001625297-25-000016 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Indivior Pharmaceuticals, Inc. — all facts · Net Income · Operating Income